Who is sponsoring NCT05651880?

NCT05651880 is sponsored by University Hospital, Rouen.

What drugs are being tested in NCT05651880?

Interventions in NCT05651880: Baricitinib 4 MG.

What condition does NCT05651880 study?

NCT05651880 studies Active Non-anterior Non-infectious Uveitis.

Is NCT05651880 still recruiting?

NCT05651880 is currently not yet recruiting. Last updated 5 June 2026.

Last reviewed 2026-06-05 · How we verify

NCT05651880: JAKUVEITE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Not yet recruiting Phase 3 Last updated 5 June 2026

What this trial tests

Phase 3 trial testing Baricitinib 4 MG in Active Non-anterior Non-infectious Uveitis in 33 participants. Not yet recruiting.

Timeline

1 July 2026

Primary endpoint
1 December 2029

1 December 2029

Quick facts

Lead sponsor	University Hospital, Rouen
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 July 2026
Primary completion	1 December 2029
Estimated completion	1 December 2029
Sites	1 location across France

Drugs / interventions tested

Baricitinib 4 MG — full drug profile →

Conditions studied

Active Non-anterior Non-infectious Uveitis — all drugs for Active Non-anterior Non-infectious Uveitis →

Sponsor

University Hospital, Rouen

Who can join

Adults 18 to 75, any sex, with Active Non-anterior Non-infectious Uveitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of patients with complete remission
Time frame: 6 months

Sponsor's own description

The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6 months of treatment

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.
Pandey R, Bakay M, Hakonarson H. · · 2023 · cited 45× · PMID 38022642 · DOI 10.3389/fimmu.2023.1271102
Dual anti-cytokine biologic and/or targeted synthetic therapy combination in spondyloarthritis: a narrative review. Are we missing the opportunity for higher remission rates?
Vieira-Sousa E, Ávila-Ribeiro P, Fonseca JE. · · 2025 · cited 1× · PMID 40529150 · DOI 10.3389/fmed.2025.1576411
Emerging therapeutic targets in non-infectious uveitis and scleritis.
Tungsattayathitthan U, Goldstein DA, Janetos TM. · · 2026 · PMID 42221086 · DOI 10.3389/fmed.2026.1846374
Pharmacotherapy for non-infectious uveitis: spotlight on phase III clinical trials of locally injected or implanted therapeutics and systemic immunomodulatory drugs.
Shields MK, Ferreira LB, Ali SB, Dedina L, et al · · 2025 · PMID 40473986 · DOI 10.1186/s12348-025-00502-9

Verify or expand the search:

Other trials of Baricitinib 4 MG

Trials testing the same drug.

NCT05858515 — REVERSE-Long COVID-19 With Baricitinib Study · Phase 3 · withdrawn
NCT06439615 — Baricitinib for the Lung Injury Following Spontaneous SAH · Phase 2 · not yet recruiting
NCT06065046 — Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions · Phase 2 · recruiting
NCT05969730 — Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis · NA · completed
NCT05914584 — "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. · Phase 2, PHASE3 · unknown

Other University Hospital, Rouen trials

Trials by the same sponsor.

NCT07441564 — Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Jux · NA · not yet recruiting
NCT07535944 — Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors · not yet recruiting
NCT07464184 — Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension · NA · not yet recruiting
NCT07359885 — Prediction of Postoperative Pulmonary Complications in Thoracic Surgery · not yet recruiting
NCT07247500 — Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05651880 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Rouen
Last refreshed: 5 June 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05651880.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing